MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
复制标题
DOI：
10.1053/j.gastro.2019.11.312
复制
发表时间：
2020-05-01
期刊：
影响因子：
29.4
通讯作者：
George, Jacob
中科院分区：
文献类型：
--
作者：
Eslam, Mohammed;Sanyal, Arun J.;George, Jacob
与代谢功能障碍相关的脂肪肝很常见，影响四分之一的人口，并且没有批准的药物治疗。虽然药物疗法正在开发中，但反应率似乎不高。代谢性脂肪肝发病机制的异质性以及术语和定义的不准确性需要重新评估命名法，以告知临床试验设计和药物开发。一组专家试图整合目前对非酒精性脂肪性肝病（NAFLD）这一首字母缩略词下患者异质性的理解，并提供有关术语的建议，这些术语更准确地反映了发病机制，并有助于患者分层管理。专家们达成共识，NAFLD并不反映当前的知识，代谢（功能障碍）相关的脂肪肝疾病“MAFLD”被认为是一个更合适的总体术语。这为研究界努力更新疾病的命名和亚表型以加速新治疗的转化途径打开了大门。
Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. Although pharmacotherapies are in development, response rates appear modest. The heterogeneous pathogenesis of metabolic fatty liver diseases and inaccuracies in terminology and definitions necessitate a reappraisal of nomenclature to inform clinical trial design and drug development. A group of experts sought to integrate current understanding of patient heterogeneity captured under the acronym nonalcoholic fatty liver disease (NAFLD) and provide suggestions on terminology that more accurately reflects pathogenesis and can help in patient stratification for management. Experts reached consensus that NAFLD does not reflect current knowledge, and metabolic (dysfunction) associated fatty liver disease “MAFLD” was suggested as a more appropriate overarching term. This opens the door for efforts from the research community to update the nomenclature and subphenotype the disease to accelerate the translational path to new treatments.